Literature DB >> 30725291

Alternate Settings for Infusions in Inflammatory Bowel Disease Patients: Homing in on Optimal Care.

Sasan Mosadeghi1, Sasha Taleban2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30725291     DOI： 10.1007/s10620-019-05480-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  8 in total

Review 1.  Home infusion: Safe, clinically effective, patient preferred, and cost saving.

Authors:  Jennifer M Polinski; Mary K Kowal; Michael Gagnon; Troyen A Brennan; William H Shrank
Journal:  Healthc (Amst)       Date:  2016-04-29

Review 2.  Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease.

Authors:  K T Park; Wallace V Crandall; Jacqueline Fridge; Ian H Leibowitz; Marc Tsou; Dana M H Dykes; Edward J Hoffenberg; Michael D Kappelman; Richard B Colletti
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 3.  ASHP Guidelines on Evaluating and Using Home or Alternate-Site Infusion Service Providers.

Authors:  Barbara Petroff; Cathy Johnson
Journal:  Am J Health Syst Pharm       Date:  2016-06-15       Impact factor: 2.637

4.  Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.

Authors:  Cédric Duron; Marion Goutte; Bruno Pereira; Gilles Bommelaer; Anthony Buisson
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-06       Impact factor: 2.566

5.  Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Elaine Barfield; Robbyn Sockolow; Edward Hoffenberg; Shehzad Saeed; Sandra Kim; Leah Siebold; Joseph Picoraro; Jonathan Moses; Dana Dykes; Andrew Grossman; Ghassan Wahbeh; K T Park
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-04       Impact factor: 2.839

6.  A home infliximab infusion program.

Authors:  Adria A Condino; Sara Fidanza; Edward J Hoffenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-01       Impact factor: 2.839

7.  Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Samiyeh Price; Wayne Langholff; Anil Londhe; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2012-08-14       Impact factor: 10.864

8.  Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.

Authors:  L Allyson Checkley; Loretta Kristofek; Samantha Kile; William Bolgar
Journal:  Dig Dis Sci       Date:  2018-10-11       Impact factor: 3.199
  8 in total
  1 in total

1.  Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.

Authors:  Louise Rath; Maria Pia Campagna; Jim Stankovich; Julian Ellis; Vilija Jokubaitis; Denise McCarthy; Cassie Nesbitt; Wei Zhen Yeh; Michael Zhong; Robb Wesselingh; Mastura Monif; Janene Richards; Viet Bui Minh; Olga Skibina; Helmut Butzkueven; Anneke van der Walt
Journal:  Int J MS Care       Date:  2020-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.